Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AP1189 in early rheumatoid arthritis
NCT06671054Phase 2Recruiting
- Sponsor
- SynAct Pharma AB
- Start
- Oct 2024
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 2, randomised, double-blind trial of resomelagon in rheumatoid arthritis (RA) (4 arms), sponsored by SynAct Pharma AB. Primary endpoint: Disease Activity Score 28 - C-Reactive Protein at 12 weeks. Started Oct 2024; status: recruiting.
02
Drugs
resomelagon
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT06671054.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06671054.